IVI’s Director-General Dr. Jerome Kim delivered the opening speech at the International Vaccine Industry Forum 2019 in Andong, S. Korea
September 20, 2019, SEOUL, Korea — The International Vaccine Institute (IVI) joined forces with the Gyeongbuk Institute for Bioindustry (GIB) to organize the ‘2019 International Vaccine Industry Forum (IVIF 2019)’ in Andong, South Korea on September 19. The event was jointly hosted by Gyeongsangbuk-do Province and Andong City to help accelerate the development of the global vaccine industry and a vaccine industry cluster in the city.
The International Vaccine Industry Forum, which has convened every year since 2016, aims to share the latest vaccine industry trends and innovative technology advances, and explore development strategies for the vaccine industry. The event also offers a venue for discussion to promote Andong, home to IVI’s branch laboratory, vaccine companies and research facilities, as an emerging global vaccine hub.
Under the overall theme of “Development and Prospect of the Vaccine Industry through Public-Private Cooperation,” this year’s event entailed in-depth discussions about public and private partnership starting with a keynote speech, followed by two main sessions and a panel discussion.
Following the opening ceremony, Clement Lewin, Senior Vice President of Sanofi Pasteur R&D, delivered his keynote speech about the current situation and the future of collaboration between public and private sectors in vaccine development and industrialization, addressing the theme of “The Role of Public Private Partnerships in Vaccines.”
IVI Director-General Dr. Jerome H. Kim chaired Session 1, which delved into “Current Status and Prospect of Public-Private Partnerships in Vaccine Research and Development.” Presenters included Dr. Anh Wartel, Head of IVI’s Clinical Development and Regulatory Department; Sung-Youl Ko, a scientist from the Vaccine Research Center at the US National Institutes of Health; Dong-Ho Kim, CEO of NA Vaccine; and Dr. Johan Holst, a senior scientist from the Coalition for Epidemic Preparedness Innovations (CEPI), who presented the current situation of vaccine development in their organizations, as well as success stories and direction of cooperation for innovation between the public and private sectors to accelerate development and commercialization of vaccines.
Session 2 was chaired by SJ Ahn, former CEO of Janssen Vaccine, and addressed the theme of “Public and Private Cooperation Roadmap to Promote Vaccine Market.” This session featured presenters including Alexander Kort, Senior Vice President of Themis Bio; Flora Bio AS, CEO of Aziz Cayli; Kim Hun, CTO of SK biosciences; and Jung-hwan Park, executive director of technology at Quad Medicine, who shared the direction of public and private cooperation in the global vaccine industry, and explored the possibility and ways to build a cooperation roadmap.
The panel discussion session, chaired by Prof. Eun-kyu Lee of Hanyang University, included in-depth discussions about success stories, issues and solutions, and growth potential between presenters in sessions 1 and 2, under the theme “Development of the Vaccine Industry through Public and Private Cooperation.” In addition, the discussants sought to discover agendas needed to accelerate the development of the vaccine industry in Korea and worldwide, while advancing international cooperation to generate win-win situations to bolster the vaccine market, and present visions for the future by discussing strategies and key solutions to accelerate innovation.
The forum also operated exhibition booths set up by SK Bioscience, the Animal Cell Culture Substantiation Center, and GIB based in Andong, which provided participants with an opportunity to learn about the vaccine industry in Andong and their vaccine projects.
Key participants pose for a commemorative photo at the International Vaccine Industry Forum 2019, where they convened to share the latest vaccine industry trends and technological advances, and explored development strategies for the industry.